Phase II, Randomized Trial of Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma.

Trial Profile

Phase II, Randomized Trial of Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Patients With Metastatic Renal Cell Carcinoma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib
  • Indications Renal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 19 Jul 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Sep 2009 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top